Items tagged with Treatment
Efficacy results of Otsuka’s delamanid (Deltyba™) for XDR-TB published in the New England Journal of Medicine (post with simple image)
Analysis of data from Phase IIb trial showed that delamanid plus a background regimen may be a promising treatment option in complex, difficult-to-treat XDR-TB patients.i
Uzbekistan: “Please, never give up. You too can beat TB.” (post with simple image)
Tetyana Pylypenko is from Ukraine and has been working with MSF for over 10 years in her home country and abroad. She comes from a nursing background, and in 2014 held the position of Medical Team Leader in Nukus, Karakalpakstan region, Uzbekistan. Below she explains more about her work with tuberculosis (TB) patients.
Tuberculosis in adults and children (post with simple image)
A monograph written for healthcare workers in any setting who are faced with the complex care for patients with tuberculosis.
Urgent need to scale up access to new treatment options for MDR-TB in the Philippines (post with simple image)
Given the urgent need to address the MDR-TB epidemic in the Philippines, advocates urge for rapid delivery of the new treatment options to people with MDR-TB.
Compassionate and optimum use of new tuberculosis drugs (post with simple image)
A report about a patient with the most resistant strain of tuberculosis documented in the USA whose inability to access combination bedaquiline and delamanid compromised his care and created a public health risk.
Life-saving drug stopped by sole supplier (post with simple image)
South Africa is running out of an essential medicine for treating very sick patients with tuberculosis (TB) and drug-resistant bacterial infections. Many hospitals are already out of stock.
Intravenous rifampicin reintroduced in South Africa (post with simple image)
Equity Pharmaceuticals is the new supplier of the drug.
New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid (post with simple image)
As countries improve and scale up their diagnostic services, increasing number of patients with multidrug-resistant TB and extensively drug-resistant TB are identified. Bedaquiline and delamanid offer a real opportunity to improve the outcomes of these patients. After so many decades without new TB drugs the development of these two new medicines is an historic opportunity to gain ground in the fight against TB.
Do we have the will to stop TB? (post with simple image)
Doctors swear to do no harm, but I knew I was about to inflict great suffering on my patient Gary, who had been diagnosed with extensively drug-resistant tuberculosis, or XDR TB. Many people wrongly assume that tuberculosis has been eradicated. In fact, according to the World Health Organization, tuberculosis killed more people in 2015 than HIV/AIDS.
Page 52 of 57 · Total posts: 0←First 51 52 53 Last→